| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Lead DOR inhibitor ADC Solid tumors | Pre-clinical | — | - | - | ||
Pre-clinical data readout example | Lead DOR inhibitor ADC Solid tumors | Pre-clinical | — | - | - | ||
Pre-clinical data readout example | Lead DOR inhibitor ADC Solid tumors | Pre-clinical | — | - | - |
Recent Updates
Recently added Catalysts
TuHURA Biosciences, Inc.$2.32
+0.13 (+5.94%)
D 39Pipeline Score Overvalued Biotech · Clinical
Market Cap
159.21 M
EPS
-0.60
P/E Ratio
-
Value Trade
1.03 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
5.23 M
Operating CF
-4.41 M
Total Assets
29.70 M
Total Liabilities
6.51 M
Equity
23.19 M
D/E Ratio
12,345
2.88 %
Week
-10.07 %
1 Month
113.68 %
3 Month
56.25 %
6 Month
-99.9 %
5 Year
-100 %
All Time
Cash Data
Cash Position
6.30 M
Monthly Burn
1.47 M
Runway
3.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
436.82 K
52 Week Range
0.41 - 3.90
% held by Insiders
34.65 %
% held by Institutions
14.81 %
Enterprise Value
153.64 M
Total Shares
63.75 M
Short %
34.75 %
Float Shares
24.29 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D39
Pipeline Score $53M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 57%
Micro Cap (rank 390 of 905)
Percentile RankTuHURA Biosciences, Inc. faces pipeline headwinds (39/100), with $1.5B risk-adjusted pipeline value, led by dalazatide in Plaque Psoriasis (Phase 1), across $56B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| dalazatide Small molecule | Plaque Psoriasis | Phase 1 | NCT02435342 | 20% | $1.0B | COMPLETED | 24 | - | - | Mar 1, 2015 | - | May 6, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IFx-2.0 | advanced or metastatic Merkel cell carcinoma | Phase 3 | 2025-06-24 | |||
IFx-2.0 | advanced or metastatic Merkel cell carcinoma | Phase 3 | 2025-06-24 | |||
IFx-2.0 | advanced or metastatic Merkel cell carcinoma | Phase 3 | 2025-06-24 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
HURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HURA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
HURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest TuHURA Biosciences, Inc. (HURA) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How HURA ranks across every disease it competes in No competitive intelligence available for HURA.